Last reviewed · How we verify
NCT03775057
Use of the MyDose Coach Digital Tool for Self-titration of Insulin in Patients With Type 2 Diabetes
NA trial testing MyDoseCoach app in Diabetes Mellitus, Type 2 in 300 participants. Status unknown.
22 June 2019
Quick facts
| Lead sponsor | Hospital Universitario Dr. Jose E. Gonzalez |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 300 |
| Start date | 22 August 2018 |
| Primary completion | 22 June 2019 |
| Estimated completion | 22 August 2019 |
| Sites | 1 location across Mexico |
Drugs / interventions tested
- MyDoseCoach app
Conditions studied
- Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
Sponsor
Hospital Universitario Dr. Jose E. Gonzalez
Who can join
Adults 18 to 75, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Scientific studies show that the introduction of digital tools led to: Significant improvement in glycemic control, greater patient satisfaction, reduction of emotional burden, reduction of fear of hypoglycaemia, reduction of anxiety of the regimen, significantly fewer of additional visits to the doctor in addition to those scheduled and a reduction of resources. Primary Objective: To evaluate the efficacy and safety of the MyDose Coach digital tool in patients with T2D with basal insulin or candidates for the use of basal insulin. Secondary Objectives: Evaluate demographic variables and control variables (HbA1c, SMPG, FPG). Measure the units of insulin used before and after the intervention
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effect of Digital-Tool-Supported Basal Insulin Titration Algorithm in Reaching Glycemic Control in Patients with Type 2 Diabetes in Mexico.
Tamez-Pérez HE, Deceased Author, Cantú-Santos OM, Gutierrez-González D, et al · · 2022 · cited 9× · PMID 34323110 · DOI 10.1177/19322968211034533
Verify or expand the search:
- PubMed search for NCT03775057
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes Mellitus, Type 2
Currently open trials in the same condition.
- NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
- NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
- NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
- NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
- NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
Other Hospital Universitario Dr. Jose E. Gonzalez trials
Trials by the same sponsor.
- NCT07401992 — Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis · Phase 4 · recruiting
- NCT06758375 — Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients · Phase 2 · recruiting
- NCT06904599 — Efficacy of Human Chorionic Gonadotropin in Acute GVHD Treatment · Phase 2 · recruiting
- NCT07039877 — Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients · Phase 2 · recruiting
- NCT06209190 — Safety and Feasibility of TMLI as Conditioning Regimen in Allogeneic Hematopoietic Stem-cell Transplantation · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03775057 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Universitario Dr. Jose E. Gonzalez
- Last refreshed: 17 December 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03775057.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing